From PsychonautWiki
(Redirected from 2CE)
Jump to navigation Jump to search
Summary sheet: 2C-E
Chemical Nomenclature
Common names 2C-E, Eternity[1], "Aquarust"[1]
Substitutive name 2,5-Dimethoxy-4-ethylphenethylamine
Systematic name 2-(4-Ethyl-2,5-dimethoxyphenyl)ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 2 mg
Light 5 - 10 mg
Common 10 - 15 mg
Strong 15 - 30 mg
Heavy 30 mg +
Total 6 - 10 hours
Onset 15 - 45 minutes
Come up 1 - 2 hours
Peak 3 - 5 hours
Offset 2 - 3 hours
After effects 6 - 24 hours

Threshold 1 mg
Light 1 - 4 mg
Common 4 - 7 mg
Strong 7 - 14 mg
Heavy 14 mg +
Onset 1 - 2 minutes
Peak 2 - 4 hours
Offset 1 - 2 hours
After effects 2 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


2,5-Dimethoxy-4-ethylphenethylamine (also known as 2C-E, or colloquially as "Aquarust"[1] and "Eternity"[1]) is a lesser-known psychedelic substance of the phenethylamine class. It is a member of the 2C-x family of psychedelic phenethylamines, which are closely related to the classical psychedelic mescaline. Like other psychedelics, it is thought to produce its effects by binding to serotonin receptors in the brain, although the precise mechanism is poorly understood.

2C-E was first synthesized and tested for human activity by Alexander Shulgin in 1977,[2] who documented his findings in the 1991 book PiHKAL ("Phenethylamines I Have Known and Loved").[3] It began to appear in drug seizures around 2004.[4] While primarily distributed online as a research chemical, it is also sometimes distributed on the street as 'mescaline' or 'synthetic mescaline'.

Subjective effects include open and closed-eye visuals, time distortion, enhanced introspection, ego loss, and euphoria. User reports characterize 2C-E as a highly unpredictable, dose-sensitive psychedelic that is capable of producing strong visual distortions along with a significant "body load", which includes nausea and bodily discomfort.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-E, and it has a limited history of human use. Many reports indicate that the safe use of this substance may be overly difficult for those who are not already experienced with hallucinogens. It is highly advised to use harm reduction practices if using this substance.

History and culture

History icon.svg

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

2C-E was first synthesized and tested for human activity by Alexander Shulgin in 1977,[2] who documented his findings in the 1991 book PiHKAL ("Phenethylamines I Have Known and Loved").[3] It is a member of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine-derived compounds, all of which except mescaline he developed and synthesized himself. They are found within the first book of PiHKAL, and are as follows: Mescaline, DOM, 2C-B, 2C-E, 2C-T-2 and 2C-T-7.


2C-E or 2,5-dimethoxy-4-ethylphenethylamine is a phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-E contains methoxy functional groups CH3O- attached to carbons R2 and R5 and an ethyl chain bound to carbon R4 of the phenyl ring. 2C-E belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.[3]


Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

2C-E's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience remains the subject of ongoing scientific investigation.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Combination effects

  • Cannabis - When used in combination with cannabis, both the visual and cognitive effects of 2C-E can be intensified and extended with extreme efficiency. This should be used with extreme caution if one is not experienced with psychedelics as this can also amplify the anxiety, confusion and psychosis producing aspects of cannabis significantly.
  • Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of 2C-E have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations, and corresponding confusion which can spontaneously manifest as delusions and psychosis.
  • MDMA - When used in conjunction with MDMA, the physical and cognitive effects of MDMA are amplified. The visual, physical and cognitive effects of 2C-E are also intensified with an overwhelming euphoric pleasure manifested through uniquely pleasurable body highs and headspaces, and uniquely colorful and awe-inspiring visuals. The synergy between these substances is unpredictable, and it is best to start with markedly lower dosages than one would take for both substances individually. Additionally, users should be aware that there are reasons to believe that this combination may result in unforeseen neurotoxic effects, so a strong sense of caution and independent research are highly advised if one decides to experiment with this combination.[citation needed]
  • Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration, nausea and physical fatigue which can negatively affect a trip if taken in moderate to high dosages. This combination is, however, typically considered to be safe in low doses and can often "take the edge off" a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit in a more physically distressing manner.
  • Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of an 2C-E trip. They are very efficient at stopping "bad trips" at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between these substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with significantly lower dosages than one would take for either substance individually.

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 2C-E use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-E is a research chemical with a limited history of human usage.

Anecdotal reports suggest that there are no negative health effects attributed to simply trying this substance by itself at low to moderate doses and using it very sparingly (although nothing can be completely guaranteed). Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance so as to ensure the accurate administration of the intended dose.

Tolerance and addiction potential

Although no formal studies have been conducted, it is not unreasonable to assume that like psychedelics in general, 2C-E is not habit-forming and that the desire to use it can actually decrease with use.

Tolerance to the effects of 2C-E is built almost immediately after ingestion. After that, it takes about 1-2 days for the tolerance to be reduced to half and 2-4 days to be back at baseline (in the absence of further consumption). 2C-E presents cross-tolerance with all psychedelics but not evenly, meaning that after the consumption of 2C-E, some psychedelics will have significant reduced effects while some others will only be slighly affected.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

  • Austria: 2C-E is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.[6]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[7]
  • Canada: 2C-E would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[8]
  • China: As of October 2015 2C-E is a controlled substance in China.[9]
  • Denmark: 2C-E is a Schedule I drug.[citation needed]
  • Finland: The possession, production and sale is illegal.[citation needed]
  • Germany: 2C-E is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[10] as of December 13, 2014.[11] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[12]
  • Israel: Possession, production and sale is illegal.[citation needed]
  • Latvia: 2C-E is a Schedule I controlled substance.[13]
  • New Zealand: 2C-E is a Class C drug.[citation needed]
  • Poland: 2C-E is a controlled substance belonging to the IV-P psychotropic group. [14]
  • Sweden: 2C-E is classified as a hazardous substance.[citation needed]
  • Switzerland: 2C-E is a controlled substance specifically named under Verzeichnis E.[15]
  • United Kingdom: 2C-E is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[16]
  • United States: 2C-E is a Schedule I drug.[17]

See also

External links



  1. 1.0 1.1 1.2 1.3 "Compound Summary: 2,5-Dimethoxy-4-ethylphenethylamine: 2.4 Synonyms". PubChem. Retrieved October 11, 2020. 
  2. 2.0 2.1 Alexander Shulgin (1980). Pharmacology Notes II (The Shulgin Lab Books) (PDF). Lafayette, CA, USA: Erowid. p. 236. 
  3. 3.0 3.1 3.2 Alexander Shulgin; Ann Shulgin (1991). "#24. 2C-E". PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264. 
  4. "2,5-Dimethoxy-4-Ethylphenethylamine (2C-E) encountered in Ft. Pierce, Florida and Royal Oak, Michigan" (PDF). Microgram Bulletin. Drug Enforcement Agency. 37 (11): 193–194. November 2004. OCLC 54464390. 
  5. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  6. "Bundesrecht konsolidiert: Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Verordnung" (in German). June 26, 2019. Retrieved January 10, 2021. 
  7. "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]. December 5, 2016. 
  8. "Schedule III". Controlled Drugs and Substances Act (CDSA). Isomer Design. Retrieved October 10, 2020. 
  9. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017. 
  10. "Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  11. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF). Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57 (in German). Bundesanzeiger Verlag (published December 12, 2014). December 5, 2014. p. 1999-2002. ISSN 0341-1095. OCLC 231871244. 
  12. "Gesetz über den Verkehr mit Betäubungsmitteln: § 29" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  13. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020. 
  14. https://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20220001665/O/D20221665.pdf
  15. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  16. "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020. 
  17. Ronald Weich (Assistant Attorney General) (September 30, 2011). "Additional Synthetic Drugs for Inclusion in section 202(c) of the Controlled Substances Act" (PDF). Letter to F. James Sensenbrenner Jr. (Subcommittee on Crime, Terrorism, and Homeland Security). Office of Legislative Affairs.